Clarivate and the Chinese Academy of Sciences Release Annual Collaborative Report to Identify 125 Research Fronts
Revealing highly active specialties in sciences and social sciences LONDON, Nov. 27,…
Aphaia Pharma to Participate in a Panel Discussion at the 1st Annual Obesity & Metabolic Innovation Forum
November 25, 2024 08:00 ET | Source: Aphaia Pharma ZUG, Switzerland and…
GREATER DES MOINES PARTNERSHIP ANNUAL DINNER SPEAKER ANNOUNCED
GREATER DES MOINES, Iowa, Nov. 20, 2024 /PRNewswire/ -- The Greater Des…
GREATER DES MOINES PARTNERSHIP ANNUAL DINNER SPEAKER ANNOUNCED
GREATER DES MOINES, Iowa, Nov. 20, 2024 /PRNewswire/ -- The Greater Des…
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
November 15, 2024 17:52 ET | Source: Protara Therapeutics NEW YORK, Nov.…
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit
Presentation to highlight advances in fibrostenotic Crohn’s Disease and the potential of…
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
November 12, 2024 16:30 ET | Source: Psyence Biomedical Ltd. NEW YORK,…
Pennant Group to Participate in the 2024 Stephens Annual Investment Conference
November 11, 2024 19:14 ET | Source: Pennant Group, Inc. EAGLE, Idaho,…
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on…
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation…